Jim Simons Aptevo Therapeutics Inc. Transaction History

Renaissance Technologies LLC

  • $63.6 Billion
  • Q1 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
BUY
$0.17 - $0.38 $57,937 - $129,507
340,809 Added 193.66%
516,789 $94,000
Q3 2023

Nov 14, 2023
BUY
$0.31 - $1.78 $29,696 - $170,513
95,794 Added 119.46%
175,980 $58,000
Q2 2023

Aug 11, 2023
BUY
$1.34 - $2.08 $33,768 - $52,416
25,200 Added 45.83%
80,186 $117,000
Q1 2023

May 12, 2023
SELL
$1.74 - $2.54 $18,270 - $26,670
-10,500 Reduced 16.03%
54,986 $112,000
Q4 2022

Feb 13, 2023
SELL
$2.0 - $3.91 $5,800 - $11,339
-2,900 Reduced 4.24%
65,486 $152,000
Q3 2022

Nov 14, 2022
SELL
$3.12 - $4.59 $4,680 - $6,885
-1,500 Reduced 2.15%
68,386 $208,000
Q2 2022

Aug 12, 2022
BUY
$3.26 - $6.3 $35,860 - $69,300
11,000 Added 18.68%
69,886 $250,000
Q1 2022

May 13, 2022
SELL
$4.48 - $8.42 $43,904 - $82,516
-9,800 Reduced 14.27%
58,886 $346,000
Q4 2021

Feb 11, 2022
SELL
$6.48 - $17.49 $484,269 - $1.31 Million
-74,733 Reduced 52.11%
68,686 $541,000
Q3 2021

Nov 12, 2021
SELL
$15.01 - $22.16 $247,725 - $365,728
-16,504 Reduced 10.32%
143,419 $2.21 Million
Q2 2021

Aug 13, 2021
SELL
$21.85 - $30.0 $1.08 Million - $1.48 Million
-49,300 Reduced 23.56%
159,923 $3.59 Million
Q1 2021

May 13, 2021
SELL
$27.86 - $40.59 $1.26 Million - $1.83 Million
-45,200 Reduced 17.77%
209,223 $6.39 Million
Q4 2020

Feb 10, 2021
SELL
$6.21 - $48.36 $238,737 - $1.86 Million
-38,444 Reduced 13.13%
254,423 $9.33 Million
Q3 2020

Nov 13, 2020
BUY
$7.21 - $9.37 $467,929 - $608,113
64,900 Added 28.47%
292,867 $2.23 Million
Q2 2020

Aug 13, 2020
BUY
$3.11 - $9.27 $146,173 - $435,699
47,001 Added 25.97%
227,967 $1.9 Million
Q1 2020

May 14, 2020
BUY
$3.29 - $9.73 $595,378 - $1.76 Million
180,966 New
180,966 $670,000

About Aptevo Therapeutics Inc.

APVO Quotes by TradingView
  • Ticker APVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,090,640
  • Market Cap $4.07M
  • Description
  • Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...
More about APVO
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email